Clariant

Pandemic sustaining the portfolio

31/07/20 -"Clariant did quite well in the pandemic as speciality chemicals have offerings to help manage the crisis better. This does not necessarily mean they are “bullet proof” chemicals but their ..."

PDF page sample
Pages
51
Language
English
Published on
31/07/20
Download
You may also be interested by these reports :
27/02/26
BASF’s Q4 2025 sales declined due to pricing pressure despite positive volumes, with Chemicals being most affected by oversupply. Materials saw ...
27/02/26
Arkema’s Q4 2025 earnings lagged behind market estimates amid continued de-stocking and weakness in the U.S. and Europe, with Asia being the only ...
26/02/26
Clariant’s Q4 2025 sales growth was volume-led, with pricing broadly flat. Higher volumes and performance improvement initiatives drove a meaningful ...
26/02/26
Arkema’s Q4 2025 results were broadly weak despite a modest sales beat. Sales declined across segments but exceeded expectations across divisions ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO